ClinicalTrials.gg

Program

SIM0270

A development code. Also written as “[14C] SIM0270 Oral Preparation”.

Its studies are mostly in Breast Neoplasms, led by Simcere Pharmaceutical Group.

Furthest: phase 3, since Nov 5, 20245 company-led studies, 4 open or runningNext primary completion: Aug 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Simcere Pharmaceutical Group54 open or runningphase 3since Nov 5, 2024Mar 7, 2022Aug 31, 2028phase 3 · NCT06680921

Also a collaborator on its studies: nanjing-zaiming-pharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 7, 2022First study: phase 1 study in Breast NeoplasmsFirst studyNCT05293964 · 214 enrolled · China
  2. Jul 16, 2024Phase 1 study in Healthy ParticipantsNCT06536036 · 16 enrolled · China
  3. Oct 21, 2024Phase 1 study in Healthy ParticipantsNCT06654791 · 6 enrolled · China
  4. Nov 5, 2024Phase 3 study in Breast NeoplasmsNCT06680921 · 482 enrolled · China
  5. Jan 2, 2026Phase 1 study in Healthy Adult ParticipantsNCT07357610 · 60 planned · China

Ahead

  1. Aug 31, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT06680921

TargetBeta

ESR1 →read by rule
“SIM0270 is an oral, selective estrogen receptor degrader (SERD)”study text, by rule · the study

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07357610Healthy Adult Participants · China1RecruitingOct 30, 202660
NCT06680921Breast Neoplasms · China3Active, not recruitingAug 31, 2028482
NCT06654791Healthy Participants · China1Active, not recruitingMar 31, 20256
NCT06536036Healthy Participants · China1CompletedOct 16, 202416
NCT05293964Breast Neoplasms · China1Active, not recruitingDec 31, 2024214

How it is read

Names in the registry

  • “SIM0270”, 4 entries
  • “[14C] SIM0270 Oral Preparation”, 1 entry

Codes read as this program: SIM0270.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.